October 2023

Dear Members of the GSDIa Community,

We hope that this letter finds you and your families well.

Ultragenyx recognizes the GSDIa community's interest in our ongoing research and we want to ensure that you have access to timely and accurate information. Below please find updates regarding the development of DTX401, our investigational gene therapy for the potential treatment of GSDIa, and some of our engagements with the global community in the first half of 2023.

Status of GlucoGene, Our Global Phase 3 Study

This study is ongoing, and all patients have been enrolled at 17 sites across eight countries. DTX401/Placebo dosing visits are complete for Year 1 and ongoing for Year 2. Study visits to assess safety and efficacy following treatment are also ongoing. Ultragenyx, study site physicians, and study teams are working closely together to support all patients and their families in their ongoing study participation to collect safety and efficacy data.

Ultragenyx and the study sites are grateful for the participation of all patients and families who are contributing to this program and appreciate their commitment in completing this study. The totality of data collected over the entire study duration and from each study participant play a critical role in understanding the potential benefits and risks of DTX401 and in planned data submissions to regulatory agencies like the European Medicines Agency (EMA) in the EU or the Food and Drug Administration (FDA) in the US. Ultimately, our goal is to gain approval for the entire GSDIa community. This research would not be possible without you.

As the blinded study is ongoing, Ultragenyx does not have safety or efficacy data to share at this point and we expect to share preliminary results from the first 48 weeks of treatment in the first half of 2024. Results will be shared with the scientific and GSD communities when available.

Status and Results from Our Phase 1/2 Study

Ultragenyx presented the "Efficacy and safety at week 52 and up to four years in adults with glycogen storage disease type Ia (GSDIa): Results from a Phase 1/2 clinical trial and long-term follow-up study of DTX401, an AAV-8-mediated, liver-directed gene therapy" at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in May. Dr. Rebecca Riba-Wolman, Connecticut Children's Medical Center, also reviewed these results at the AGSD 2023 Conference in June, which include:

- Mean reduction in cornstarch of 70% from baseline to Week 52 that persisted for 4+ years in Cohort 1 participants
- Time in normal glucose levels (assessed by CGM) improved or remained stable
- Safety profile was similar across all participants treated in all dose cohorts and as expected for DTX401; there were no treatment related Serious Adverse Events (SAEs)
- In the Phase 1/2 study, participants were asked to complete a Patient Global Impression of Change (PGIC) questionnaire at Week 52 to rate the change in their GSDIa since the start of the study. At Week 52, ratings of improvement on the PGIC were correlated with reductions in cornstarch intake.
- The Phase 1/2 study evaluated DTX401 of varying doses and steroid regimens across 4 groups of patients with GSDIa to determine the optimal dose and regimen for the Phase 3 study
- The Phase 3 study will provide us with additional learnings and together both studies can be used in planned data submissions to regulatory agencies

As a reminder, the safety and efficacy of DTX401 have not yet been established and it has not been approved by any regulatory agencies.

Collaborating with the GSDIa Community

Our Patient Advocacy team partners with the GSDIa community and GSD patient advocacy groups to understand the experiences of patients and families and address the community's unmet needs. We're grateful to be learning from you and advancing GSDIa research together.

Scandinavian Association for GSD (SAGSD) 2023 Patient Meeting, May 2023
We attended and were proud to sponsor this event in Sweden. It was a great opportunity to learn more about the perspectives of families living in Scandinavia and the many ways in which SAGSD supports families and fosters collaborations with healthcare professionals.

ASGCT 2023 Annual Meeting, May 2023
We presented "Rare disease patient advocacy perspectives on the promise and challenges of gene therapy," an abstract outlining how Ultragenyx is working to understand the questions, expectations, and fears of communities. We discussed learnings from discussions with our Global Gene Therapy Advisory Council, a group of nine patient advocacy leaders in five countries across a range of diseases (including GSDIa) in which gene therapies are in development or are commercially available. Learnings include the importance of clinicians, advocates, patients, and biopharmaceutical companies coming together to support gene therapy decision-making.

AGSD UK, The Main Event Conference, May 2023
We presented results from "People and families affected by GSDIa: Narrative accounts written by people living with GSDIa and their caregivers," a study designed to understand the day-to-day impacts of GSDIa on people and their families. The results were also shared with the GSD community at the International Glycogen Storage Disease Conference Annual Meeting in 2022 and highlighted in Ultragenyx's new GSDIa Research Booklet, which is further referenced below. These data may be used to inform regulatory submissions and support discussions with health authorities.

AGSD 2023 Conference, June 2023
We attended and were proud to sponsor this event where we met many families involved in the US community. We also disseminated our GSDIa Research Booklet and a copy of the abstract presented at ASGCT 2023. This booklet incorporates insights collected from the community and shares examples of how Ultragenyx is working with you to advance GSDIa research through clinical trials and other research. You can download this resource in the "Ultragenyx Research > Conditions We Study > GSDIa" section at UltraRareAdvocacy.com.

Thank You!

The Ultragenyx team would like to express our sincere gratitude to the GSDIa community. You have been a strong ally throughout the development of DTX401. Thank you to the patients and families who have contributed, and continue to contribute, to this research. We will continue to share timely information with the community as the ongoing GlucoGene study progresses.

Sincerely,



Eric Crombez, MD
Chief Medical Officer